Cargando…

Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem Cells

BACKGROUND: Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide. Growing evidence indicates that tumor-initiating cells (TICs) are responsible for tumor growth and progression. Conventional chemotherapeutics do not sufficiently eliminate TICs, leading to tumor relapse. We ai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malkomes, Patrizia, Lunger, Ilaria, Luetticke, Alexander, Oppermann, Elsie, Haetscher, Nadine, Serve, Hubert, Holzer, Katharina, Bechstein, Wolf Otto, Rieger, Michael A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2016
Materias:	Colorectal Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972858/ https://www.ncbi.nlm.nih.gov/pubmed/27059026 http://dx.doi.org/10.1245/s10434-016-5218-z

Ejemplares similares

Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53
por: Malkomes, Patrizia, et al.
Publicado: (2021)

Chemotherapy and Targeted Therapy Strategies in Patients with Unresectable or Borderline Resectable Metastatic Colorectal Cancer: Evidence for a Lack of Focus on Resection Rates
por: Zmuc, Jan, et al.
Publicado: (2023)

Transglutaminase 2 is associated with adverse colorectal cancer survival and represents a therapeutic target
por: Malkomes, Patrizia, et al.
Publicado: (2023)

Differential effects of the Akt inhibitor MK-2206 on migration and radiation sensitivity of glioblastoma cells
por: Djuzenova, Cholpon S., et al.
Publicado: (2019)

A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma
por: Stover, Elizabeth H., et al.
Publicado: (2022)

Locally Advanced Colorectal Cancer: True Peritoneal Tumor Penetration is Associated with Peritoneal Metastases
por: Klaver, Charlotte E. L., et al.
Publicado: (2017)

Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo
por: Zhao, Yuan-Yuan, et al.
Publicado: (2014)

Computational Insights into the Inhibitory Mechanism of Human AKT1 by an Orally Active Inhibitor, MK-2206
por: Rehan, Mohd, et al.
Publicado: (2014)

Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis
por: Wilson, Jacob M, et al.
Publicado: (2015)

Inhibition of AKT with the Orally Active Allosteric AKT Inhibitor, MK-2206, Sensitizes Endometrial Cancer Cells to Progestin
por: Pant, Alok, et al.
Publicado: (2012)

The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy
por: Simioni, Carolina, et al.
Publicado: (2013)

Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer
por: Ahn, Daniel H., et al.
Publicado: (2015)

Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex
por: Ji, Shuang, et al.
Publicado: (2017)

MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway
por: Xiang, Ru-Fang, et al.
Publicado: (2017)

MK-2206 Alleviates Renal Fibrosis by Suppressing the Akt/mTOR Signaling Pathway In Vivo and In Vitro
por: Chen, Meiling, et al.
Publicado: (2022)

Activated neutrophils induce an hMSH2-dependent G2/M checkpoint arrest and replication errors at a (CA)13-repeat in colon epithelial cells
por: Campregher, C, et al.
Publicado: (2008)

Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition
por: Fujisawa, T, et al.
Publicado: (2008)

Prognostic Value of Resection of Primary Tumor in Patients with Stage IV Colorectal Cancer: Retrospective Analysis of Two Randomized Studies and a Review of the Literature
por: Venderbosch, Sabine, et al.
Publicado: (2011)

Diffusion-Weighted MRI for Selection of Complete Responders After Chemoradiation for Locally Advanced Rectal Cancer: A Multicenter Study
por: Lambregts, Doenja M. J., et al.
Publicado: (2011)

K-Ras and MSI: Potential Markers of Both Patient Prognosis and Treatment Efficacy
por: Turaga, Kiran, et al.
Publicado: (2009)

Using CT colonography as a triage technique after a positive faecal occult blood test in colorectal cancer screening
por: Liedenbaum, M H, et al.
Publicado: (2009)

High Lymph Node Yield is Related to Microsatellite Instability in Colon Cancer
por: Belt, E. J. Th., et al.
Publicado: (2011)

Long-Term Outcome of Patients with Complete Pathologic Response after Neoadjuvant Chemoradiation for cT3 Rectal Cancer: Implications for Local Excision Surgical Strategies
por: Belluco, Claudio, et al.
Publicado: (2011)

Is the 1-cm Rule of Distal Bowel Resection Margin in Rectal Cancer Based on Clinical Evidence? A Systematic Review
por: Bujko, Krzysztof, et al.
Publicado: (2011)

Importance of the First Postoperative Year in the Prognosis of Elderly Colorectal Cancer Patients
por: Dekker, J. W. T., et al.
Publicado: (2011)

Adjuvant Therapy for Colon Cancer: Learning from the Past to Inform the Future
por: Sargent, Daniel, et al.
Publicado: (2010)

Limited Value of Staging Squamous Cell Carcinoma of the Anal Margin and Canal Using the Sentinel Lymph Node Procedure: A Prospective Study with Long-Term Follow-Up
por: de Jong, Johannes S., et al.
Publicado: (2010)

Preoperative Staging with Chest CT in Patients with Colorectal Carcinoma: Not as a Routine Procedure
por: Grossmann, Irene, et al.
Publicado: (2010)

2010 SSO John Wayne Clinical Research Lecture: Rectal Cancer Outcome Improvements in Europe: Population-Based Outcome Registrations will Conquer the World
por: van Gijn, W., et al.
Publicado: (2010)

Clinical Translation of Ex Vivo Sentinel Lymph Node Mapping for Colorectal Cancer Using Invisible Near-Infrared Fluorescence Light
por: Hutteman, Merlijn, et al.
Publicado: (2010)

Pilot Study of Sentinel-Node-Based Adoptive Immunotherapy in Advanced Colorectal Cancer
por: Karlsson, Mona, et al.
Publicado: (2010)

Lymph Node Negative Colorectal Cancers with Isolated Tumor Deposits Should Be Classified and Treated As Stage III
por: Belt, E. J. Th., et al.
Publicado: (2010)

Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
por: Ghiringhelli, Francois, et al.
Publicado: (2014)

Use of CT colonography in the English Bowel Cancer Screening Programme
por: Plumb, Andrew A, et al.
Publicado: (2014)

Optimal Treatment Strategy in Rectal Cancer Surgery: Should We Be Cowboys or Chickens?
por: Snijders, Heleen S., et al.
Publicado: (2015)

Lymphatic Invasion is an Independent Adverse Prognostic Factor in Patients with Colorectal Liver Metastasis
por: de Ridder, Jannemarie A. M., et al.
Publicado: (2015)

Use of hospital resources in the Finnish colorectal cancer screening programme: a randomised health services study
por: Mäklin, Suvi, et al.
Publicado: (2015)

Angiogenesis-Related Markers and Prognosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer
por: de Cuba, E. M. V., et al.
Publicado: (2016)

Impact of preoperative serum albumin on 30-day mortality following surgery for colorectal cancer: a population-based cohort study
por: Montomoli, Jonathan, et al.
Publicado: (2015)

Assessment of Clinical Complete Response After Chemoradiation for Rectal Cancer with Digital Rectal Examination, Endoscopy, and MRI: Selection for Organ-Saving Treatment
por: Maas, Monique, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hkqpcf1upje8m3fc7kv30ivi75